HER2 BINDERS

1 . An imaging agent composition comprising:

an isolated polypeptide comprising SEQ. ID No 1, SEQ. ID No 2, or a conservative variant thereof, conjugated with a 99m Tc via a diaminedioxime chelator;

wherein the isolated polypeptide binds specifically to HER2, or a variant thereof.

2 . An imaging agent composition comprising:

an isolated polypeptide comprising SEQ. ID No 1, SEQ. ID No 2, or a conservative variant thereof, conjugated with 67 Ga or 68 Ga via a NOTA chelator;

wherein the isolated polypeptide binds specifically to HER2, or a variant thereof.

3 . An imaging agent composition comprising:

an isolated polypeptide comprising SEQ. ID No 1, SEQ. ID No 2, or a conservative variant thereof, conjugated with 18 F via a linker;

wherein the linker comprises a group derived from an aminoxy group, an azido group, or an alkyne group; and

wherein the isolated polypeptide binds specifically to HER2, or a variant thereof.

4 . The composition of claim 1 , wherein the diaminedioxime chelator comprises Pn216, cPn216, Pn44, or derivatives thereof.

5 . The composition of claim 3 , wherein the 18 F is attached to the isolated polypeptide via the aminoxy linker at (the) N-terminus of the isolated polypeptide.

6 . The composition of claim 4 , wherein the 99m Tc is conjugated to the isolated polypeptide via the cPn216 chelator at (the) N-terminus of the isolated polypeptide.

7 . A method of imaging at least a portion of a subject comprising:

administering the composition of claim 1 to the subject, and

imaging the subject with a diagnostic device.

8 . The method of claim 7 , further comprising the steps of:

monitoring delivery of the composition of claim 1 to the subject; and

diagnosing the subject with a HER2-associated disease condition.

9 . A method of imaging at least a portion of a subject comprising:

administering the composition of claim 2 to the subject, and

imaging the subject with a diagnostic device.

10 . The method of claim 9 , further comprising the steps of:

monitoring delivery of the composition of claim 2 to the subject; and

diagnosing the subject with a HER2-associated disease condition.

11 . A method of imaging at least a portion of a subject comprising:

administering the composition of claim 3 to the subject, and

imaging the subject with a diagnostic device.

12 . The method of claim 11 , further comprising the steps of:

monitoring delivery of the composition of claim 2 to the subject; and

diagnosing the subject with a HER2-associated disease condition.

13 . The method of claim 12 , wherein the HER2-associated disease condition is breast cancer.

14 . The method of claim 11 , wherein the diagnostic device employs an imaging method selected from the group consisting of MRI, PET, SPECT, radioimaging, and combinations thereof.

15 . A method for preparing a chelator conjugated polypeptide composition comprising:

(i) providing an isolated polypeptide comprising SEQ. ID No 1 or SEQ. ID No 2, or a conservative variant thereof;

(ii) reacting a diaminedioxime chelator with the polypeptide to form the chelator conjugated polypeptide.

16 . The method of claim 15 , wherein the diaminedioxime chelator is conjugated with 99m Tc.

17 . A method for preparing a 18 F conjugated polypeptide composition comprising:

(i) providing an isolated polypeptide comprising SEQ. ID No. 1 or SEQ. ID No. 2 or a conservative variant thereof;

(ii) reacting the polypeptide with a linker wherein the linker comprises a group derived from an aminoxy group, an azido group, or an alkyne group; and

(iii) reacting the linker with a 18 F moiety to form the 18 F conjugated polypeptide.